Publication
Article
Pharmacy Practice in Focus: Health Systems
CE: Updates in Myasthenia Gravis Treatment for Specialty Pharmacists
Myasthenia gravis is most commonly caused by binding of immunoglobulin G (IgG) antibodies to the postsynaptic acetylcholine receptor (AChR), although other receptors may also be involved.
THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM CSL BEHRING LLC.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
• Examine the pathophysiology and disease progression of myasthenia gravis
• Explore the available treatment approaches for myasthenia gravis and myasthenic crisis
• Identify opportunities of intervention for specialty pharmacists to improve patient care and outcomes in management of myasthenia gravis
FACULTY
Michael Erdman, PharmD, BCPS
Critical Care Pharmacist, Neuroscience Intensive Care Unit, UF Health Jacksonville, Jacksonville, Florida
TARGET AUDIENCE: Pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: June 15, 2020
EXPIRATION DATE: June 15, 2021
ESTIMATED TIME TO COMPLETE ACTIVITY: 2 hours
FEE: This lesson is offered for free at www.pharmacytimes.org.
